



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider the use of nucleic acid testing using a direct or amplified probe technique (without quantification of viral load) to be **eligible for coverage**** for the following microorganisms:

- *Bartonella henselae* or *Quintana*
- *Bordetella pertussis*
- *Candida* species
- *Chlamydia pneumoniae*
- *Chlamydia trachomatis*
- *Clostridium difficile*
- *Enterococcus*, vancomycin-resistant (eg, enterococcus vanA, vanB)
- *Enterovirus*
- Herpes simplex virus
- Human papillomavirus
- Influenza virus
- *Legionella pneumophila*
- *Mumps*
- *Mycobacterium* species
- *Mycobacterium tuberculosis*
- *Mycobacterium avium intracellulare*
- *Mycoplasma pneumoniae*
- *Neisseria gonorrhoeae*

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

- *Rubeola (measles)*
- *Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for indications consistent with the Centers for Disease Control and Prevention (CDC) guidance related to COVID-19 testing*
- *Staphylococcus aureus*
- *Staphylococcus aureus, methicillin resistant*
- *Streptococcus, group A*
- *Streptococcus, group B*
- *Trichomonas vaginalis*
- *Zika virus*

Note: SARS-CoV2 testing required for work, school and recreational activities is excluded from coverage.

Based on review of available data, the Company may consider the use of nucleic acid testing using a direct or amplified probe technique (with or without quantification of viral load) to be **eligible for coverage**** for the following microorganisms:

- Cytomegalovirus
- Hepatitis B virus
- Hepatitis C virus
- HIV-1
- HIV-2
- Human herpesvirus 6

Based on review of available data, the Company may consider the use of the Respiratory Pathogen nucleic acid testing panel (without quantification of viral load) for patients with signs and symptoms of a respiratory infection when the result of testing is actionable and likely to guide treatment to be **eligible for coverage.****

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

Based on review of available data, the Company considers the use of nucleic acid testing with quantification of viral load to be **investigational*** for microorganisms that are not included in the list of microorganisms for which probes with or without quantification are considered to be eligible for coverage.**

Based on review of available data, the Company considers the use of nucleic acid testing using a direct or amplified probe technique to be **investigational*** for the following microorganisms:

- *Gardnereella vaginalis*
- *Hepatitis G virus*

Based on review of available data, the Company considers the use of the following nucleic acid testing panels (with or without quantification of viral load for viral panel elements) to be **investigational***:

- *Central nervous system pathogen panel*
- *Gastrointestinal pathogen panel*

Based on review of available data, the Company considers multitarget polymerase chain reaction testing for the diagnosis of bacterial vaginosis (including testing for *Atopobium vaginae*, *Lactobacillus* species, *G. vaginalis*, *Megasphaera* species, *Mycoplasma hominis*, *Peptostreptococcus*, *Mobiluncus* species, and other anaerobic gram-negative rods) to be **investigational***

Policy Guidelines

Vaccine-preventable diseases surveillance for outbreaks and diagnosis of isolated cases: the CDC Pertussis and Diphtheria Laboratory has developed its own PCR and serological assays to diagnose pertussis, mumps and rubeola (measles) and has recommendations for their appropriate use.

For *Candida* species, culture for yeast remains the criterion standard for identifying and differentiating these organisms. Although sensitivity and specificity are higher for nucleic acid amplification tests (NAATs) than for standard testing methods, the CDC and other association guidelines do not recommend NAATs as first-line testing for *Candida* species. The CDC (2015) classifies uncomplicated vulvovaginal candidiasis as being sporadic or infrequent; or mild to moderate; or, in nonimmunocompromised women, as likely to be caused by *C. albicans*. A

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

presumptive diagnosis can be made in the clinical care setting. However, for complicated infections, the CDC states that NAATs may be necessary to test for multiple *Candida* subspecies. Complicated vulvovaginal candidiasis is classified as being recurrent or severe; or, in women with uncontrolled diabetes, debilitation, or immunosuppression, as less likely to be caused by a *C. albicans* species.

Antibiotic sensitivity of streptococcus A culture is generally not performed for throat cultures. However, if an antibiotic sensitivity is considered, then the most efficient method of diagnosis would be a combined culture and antibiotic sensitivity.

In the evaluation of group B streptococcus, the primary advantage of a DNA probe technique compared with traditional culture techniques is the rapidity of results. This advantage suggests that the most appropriate use of the DNA probe technique is in the setting of impending labor, for which prompt results could permit the initiation of intrapartum antibiotic therapy.

Use of NAAT for SARS-CoV-2 is for confirming Coronavirus Disease 2019 (COVID-19) diagnoses. This medical policy does not address antibody testing (serological IgG assays).

It should be noted that the technique for quantification includes both amplification and direct probes; therefore, simultaneous coding for both quantification with either amplification or direct probes is not warranted.

Many probes have been combined into panels of tests. For the purposes of this policy, other than the respiratory pathogen panel, gastrointestinal pathogen panel and, central nervous system panel, only individual probes are reviewed.

Background/Overview

Nucleic Acid Probes

A nucleic acid probe is used to detect and identify species or subspecies of organisms by identifying nucleic acid sequences in a sample. Nucleic acid probes detect genetic materials, such as RNA or DNA, unlike other tests, which use antigens or antibodies to diagnose organisms.

The availability of nucleic acid probes has permitted the rapid direct identification of microorganism DNA or RNA. Amplification techniques result in exponential increases in copy numbers of a

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

targeted strand of microorganism-specific DNA. The most used amplification technique is polymerase chain reaction (PCR) or reverse transcriptase PCR. In addition to PCR, other nucleic acid amplification techniques have been developed, such as transcription-mediated amplification, loop-mediated isothermal DNA amplification, strand displacement amplification, nucleic acid sequence-based amplification, and branched-chain DNA signal amplification. After amplification, target DNA can be readily detected using a variety of techniques. The amplified product can also be quantified to assess how many microorganisms are present. Quantification of the number of nucleic acids permits serial assessments of response to treatment; the most common clinical application of quantification is the serial measurement of HIV RNA (called viral load).

The direct probe technique, amplified probe technique, and probe with quantification methods vary based on the degree to which the nucleic acid is amplified and the method for measurement of the signal. The direct probe technique refers to detection methods in which nucleic acids are detected without an initial amplification step. The amplified probe technique refers to detection methods in which either target, probe, or signal amplification is used to improve the sensitivity of the assay over direct probe techniques, without quantification of nucleic acid amounts.

- Target amplification methods include PCR (including PCR using specific probes, nested or multiplex PCR), nucleic acid-based sequence amplification, transcription-mediated amplification, and strand displacement amplification. Nucleic acid-based sequence amplification and transcription-mediated amplification involve amplification of an RNA (rather than a DNA) target.
- Probe amplification methods include ligase chain reaction.
- Signal amplification methods include branched DNA (bDNA) probes and hybrid capture methods using an anti-DNA/RNA hybrid antibody.

The probe with quantification techniques refers to quantitative PCR or real-time PCR methods that use a reporter at each stage of the PCR to generate absolute or relative amounts of a known nucleic acid sequence in the original sample. These methods may use DNA-specific dyes (ethidium bromide or SYBR green), hybridization probes (cleavage-based [TaqMan] or displaceable), or primer incorporated probes.

Direct assays will generally have lower sensitivity than amplified probes. In practice, most commercially available probes are amplified, with a few exceptions. For this evidence review,

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

indications for direct and/or amplified probes without quantification are considered together, while indications for a probe with quantification are considered separately.

Classically, identification of microorganisms relies either on the culture of body fluids or tissues or identification of antigens, using a variety of techniques including direct fluorescent antibody technique and qualitative or quantitative immunoassays. These techniques are problematic when the microorganism exists in very small numbers or is technically difficult to culture. Indirect identification of microorganisms by immunoassays for specific antibodies reactive with the microorganism is limited by difficulties in distinguishing between past exposure and current infection.

Potential reasons for a nucleic acid probe to be associated with improved clinical outcomes compared with standard detection techniques include the following (note: in all cases, for there to be clinical utility, making a diagnosis should be associated with changes in clinical management, which could include initiation of effective treatment, discontinuation of other therapies, or avoidance of invasive testing):

- Significantly improved speed and/or efficiency in making a diagnosis.
- Improved likelihood of obtaining any diagnosis in cases where standard culture is difficult. Potential reasons for difficulty in obtaining standard culture include low numbers of the organisms (eg, HIV), fastidious or lengthy culture requirements (eg, *Mycobacteria*, *Chlamydia*, *Neisseria* species), or difficulty in collecting an appropriate sample (eg, herpes simplex encephalitis).
- There is no way to definitively make a diagnosis without nucleic acid testing.
- The use of nucleic acid probe testing provides qualitatively different information than that available from standard cultures, such as information regarding disease prognosis or response to treatment. These include cases where quantification of viral load provides prognostic information or is used to measure response to therapy.

The risks of nucleic acid testing include false-positive and false-negative results, inaccurate identification of pathogens by the device, inaccurate interpretation of test results, or incorrect operation of the instrument.

- False-positive results can lead to unnecessary treatment, with its associated toxicities and side effects, including allergic reaction. In addition, true diagnosis and treatment could be delayed or missed altogether.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

- False-negative results could delay diagnosis and initiation of proper treatment.
- It is possible that these risks can be mitigated by the use of a panel of selected pathogens indicated by the clinical differential diagnosis while definitive culture results are pending.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

The U.S. FDA maintains a list of NAATs that have been cleared by the Center for Devices and Radiological Health. These NAATs have been cleared for many of the microorganisms discussed in this review and may be reviewed on this site.

Table 1 summarizes the NAATs cleared for central nervous system panels when diagnosing meningitis and/or encephalitis, for panels when diagnosing gastroenteritis, and for respiratory panels.

Table 1. FDA Cleared Nucleic Acid Amplification Tests for Central Nervous System, Gastrointestinal, and Respiratory Panels

NAAT	Manufacturer	510(k) Number	Product Code
Meningitis/Encephalitis (CNS) Pathogen Panels			
FilmArray Meningitis/Encephalitis Panel	BioFire Diagnostics, LLC (Salt Lake City, UT)	DEN150013, K160462	PLO
Gastroenteritis Pathogen Panels			
xTAG Pathogen Panel (GPP)	Luminex Molecular Diagnostics, Inc (Toronto, Ontario, CA)	DEN130003, K121454	PCH
Progestro SSCS Assay	Gen-Probe Prodesse, Inc (Waukesha, WI)	K123274	PCH
Biocode Pathogen Panel	Applied Biocode (Santa Fe Springs, CA)	K190585	PCH

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

EntericBio Dx Assay	Serosep, Ltd (Annacotty, IE)	K182703	PCH
Filmarray Panel	BioFire Diagnostics, LLC (Salt Lake City, UT)	K140407, K160459	PCH
ProGastro SSCS	Hologic/Genprobe (Waukesha, WA)	K123274	PCH
BD MAX Enteric Bacterial Panel (EBP)	BD Diagnostics (Sparks, MD)	K170308	PCH
Verigene Enteric Pathogen Panel (EP)	Nanosphere, Inc (Northbrook, IL)	K142033, K140083	PCH
xTAG Gastroenterology Pathogen Panel (GPP) Multiplex Nucleic Acid-Based Assay System	Luminex Molecular Diagnostics, Inc (Toronto, Ontario, CA)	K121894	PCH
FilmArray GI Panel	BioFire Diagnostics, Inc (Salt Lake City, UT)	K140407	PCH
Respiratory Viral Panels			
ID-TAG Respiratory Viral Panel Nucleic Assay System	Luminex Molecular Diagnostics, Inc (Toronto, Ontario, CA)	DEN070013, K063765	OCC
Biocode Respiratory Pathogen Panel	Applied BioCode, Inc. (Santa Fe Springs, CA)	K192485	OCC
Nxtag Respiratory Pathogen Panel	Luminex Molecular Diagnostics, Inc (Toronto, Ontario, CA)	K193167	OCC

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

xTAG Respiratory Virus Panel (RVP)	Luminex Molecular Diagnostics, Inc (Toronto, Ontario, CA)	K081483	OCC
Qiastat-Dx Respiratory Panel	QIAGEN GmbH (Germantown, MD)	K183597	OCC
xTAG Respiratory Virus Panel FAST	Luminex Molecular Diagnostics, Inc (Toronto, Ontario, CA)	K103776	OCC
eSensor [®] Respiratory Virus Panel (RVP)	Clinical Micro Sensors, Inc (Carlsbad, CA)	K113731	JJH
Verigene Respiratory Pathogens Plus Nucleic Acid Test	Nanosphere, Inc (Northbrook, IL)	K103209	OCC
BioFire FilmArray Respiratory Panel (RP)	BioFire Diagnostics, Inc (Salt Lake City, UT)	K123620	OCC

;CNS: central nervous system; DEN: de novo; FDA: Food and Drug Administration.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing.

Rationale/Source

Nucleic acid probes are available for the identification of a wide variety of microorganisms. Nucleic acid probes can also be used to quantitate the number of microorganisms present. This technology offers advantages over standard techniques when rapid identification is clinically important, microbial identification using standard culture is difficult or impossible, and/or treatment decisions are based on quantitative results.

Summary of Evidence

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

For individuals who have signs and/or symptoms of meningitis and/or encephalitis who receive a nucleic acid-based central nervous system pathogen panel, the evidence includes a systematic review and a pivotal prospective study. Relevant outcomes include test accuracy and validity, other test performance measures, medication use, symptoms, and change in disease status. Access to a rapid method that can simultaneously test for multiple pathogens may lead to the faster initiation of more effective treatment and conservation of cerebrospinal fluid. The available central nervous system panel is highly specific for the included organisms, but the sensitivity for each pathogen is not well-characterized. More than 15% of positives in the largest clinical validity study were false-positives. A negative panel result does not exclude infection due to pathogens not included in the panel. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have signs and/or symptoms of gastroenteritis who receive a nucleic acid-based gastrointestinal pathogen panel, the evidence includes prospective and retrospective evaluations of the tests' sensitivity and specificity and prospective studies on utility. Relevant outcomes include test accuracy and validity, other test performance measures, medication use, symptoms, and change in disease status. The evidence suggests that pathogen panels are likely to identify both bacterial and viral pathogens with high sensitivity, compared with standard methods. Access to a rapid method for etiologic diagnosis of infections may lead to more effective early treatment and infection control measures. However, in most instances, when a specific pathogen is suspected, individual tests could be ordered. There may be a subset of patients with an unusual presentation who would warrant testing for a panel of pathogens at once, but that subset has not been well defined. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have signs and/or symptoms of respiratory infection who receive a nucleic acid-based respiratory pathogen panel, the evidence includes a systematic review and 2 randomized controlled trials (RCTs). Relevant outcomes include test accuracy and validity, other test performance measures, medication use, symptoms, and change in disease status. The systematic review reported that all 3 reviewed multiplex polymerase chain reaction systems were highly accurate. One RCT and 1 quasi-RCT evaluated utility of a respiratory panel and found benefits in time-to-treat and length of hospital stay. In addition, 1 subanalysis found fewer antibiotics being prescribed for patients diagnosed with the panel. The panel did not significantly affect duration of antibiotic use, readmission, or mortality rates. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

Supplemental Information

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

Numerous guidelines have been identified concerning the use of NAATs for the diagnosis of the pathogens discussed in this review. Table 2 provides an index of NAAT recommendation by virus/ infection.

Table 2. Index of NAAT Recommendations by Virus/Infection

Microorganism	Guidelines Recommending the Use of NAATs (Location)	Guidelines Not Recommending the Use of NAATs^a (Location)
<i>Bartonella hensalae</i>	NIH (2.1.1), IDSA (3.1), AAP (5.1)	NA
<i>Candida</i> species	CDC (1.5.1) ^b	IDSA (3.1, 3. 6), AAP (5.1)
CNS pathogen panel	IDSA (3.2, 3.3)	NA
<i>Chlamydia pneumoniae</i>	CDC (1.5.3), IDSA (3.1 ^c)	AAP (5.1)
<i>Chlamydia trachomatis</i>	CDC (1.5.2, ^c 1.6 ^c), IDSA (3.1), AAP (5.1)	NA
<i>Clostridioides (Clostridium) difficile</i>	NIH (2.1.2), AAP (5.1)	IDSA (3.1, 3.4)
Cytomegalovirus	CDC (1.1), NIH (2.1.3), IDSA (3.1, ^c 3.3)	AAP (5.1)
Enterovirus	IDSA (3.1), AAP (5.1)	NA

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

<i>Gardnerella vaginalis</i>	AAP (5.1)	CDC (1.5.4), IDSA (3.1)
GI pathogen panel	CDC (1.4 ^c), IDSA (3.5), ACG (6.1)	NA
Hepatitis B	NIH (2.1.4), IDSA (3.1), AAP (5.1)	NA
Hepatitis C	CDC (1.5.5 ^c), NIH (2.1.5), IDSA (3.1), AAP (5.1)	NA
Herpes simplex virus	CDC (1.5.6 ^c), NIH (2.1.6), IDSA (3.1, ^c 3.3), AAP (5.1)	NA
Human herpesvirus 6	IDSA (3.1, ^c 3.3)	AAP (5.1)
Human papillomavirus	CDC (1.5.8 ^c), AAP (5.1)	NA
HIV 1	CDC (1.5.7 ^c), IDSA (3.1), AAP (5.1)	NA
Influenza virus	IDSA (3.1 ^c), AAP (5.1)	NA
<i>Legionella pneumophila</i>	IDSA (3.1), AAP (5.1)	NA
Meningitis	NA	IDSA (3.2)
<i>Mycobacteriaspecies</i>	CDC (1.7), NIH (2.1.7), IDSA (3.1, 3.3)	AAP (5.1)
<i>Mycoplasma pneumoniae</i>	CDC (1.2 ^c), IDSA (3.3), AAP (5.1)	NA
<i>Neisseria gonorrhoeae</i>	CDC (1.6 ^c), IDSA (3.1), AAP (5.1)	NA
Respiratory panel	None Identified	NA
SARS-CoV-2	IDSA (3.7)	NA
<i>Staphylococcus aureus</i>	IDSA (3.1), AAP (5.1)	NA
<i>Streptococcus</i> , group A	IDSA (3.1)	AAP (5.1)
<i>Streptococcus</i> , group B	AAP (5.2), ASM (7.1)	IDSA (3.1), AAP (5.1)
<i>Trichomonas vaginalis</i>	CDC (1.5.9), IDSA (3.1), ^c AAP (5.1)	NA

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

Vancomycin-resistant <i>Enterococcus</i>	AST (4.1)	IDSA (3.1), AAP (5.1)
Zika virus	CDC (1.3), IDSA (3.1), AAP (5.1)	NA

AAP: American Academy of Pediatrics; ACG: American College of Gastroenterology; ASM: American Society for Microbiology; AST: American Society of Transplantation; CDC: Centers for Disease Control and Prevention; CNS: central nervous system; GI: ; HIV: human immunodeficiency virus; IDSA: Infectious Disease Society of America; NA: not applicable (none found); NAAT: nucleic acid amplification test; NIH: National Institutes of Health; SARS-CoV-2: *Severe acute respiratory syndrome coronavirus 2*.

^a Guidelines Not Recommending includes not only guidelines that recommend against NAATs but also those that were neutral on the use of NAATs.

^b CDC recommends culture for first-line identification of *Candida* species; it recommends NAAT for complicated infections and for second-line diagnosis.

^c Indicates guidelines in which the issuing body specifically recommends that U.S. FDA-cleared NAATs be used.

A. Centers for Disease Control and Prevention

The CDC has published 10 recommendations and statements regarding the use of NAATs to diagnose the viruses and infections discussed in this evidence review since 2009.

1.1 The CDC published guidance for laboratory testing for cytomegalovirus (CMV), the guideline stated that the standard laboratory test for congenital CMV is polymerase chain reaction (PCR) on saliva, with confirmation via urine test to avoid false-positive results from ingesting breast milk from CMV seropositive mothers. Serologic tests were recommended for persons >12 months of age.

1.2 The CDC published diagnostic methods for mycoplasma pneumoniae. They cited NAAT as a method of diagnosis, along with culture or serology.

1.3 The CDC published updated guidelines on Zika virus testing. Routine testing for Zika virus in asymptomatic pregnant patients is not recommended, but NAAT testing may still be considered for asymptomatic pregnant women with recent travel to an area with risk of Zika outside the U.S. and its territories. Symptomatic pregnant patients should receive NAAT testing if they have recently traveled to areas with a risk of Zika virus or if they have had sex with someone who lives in or

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

recently traveled to areas with risk of Zika virus. If a pregnant woman (with risk of Zika virus exposure) has a fetus with prenatal ultrasound findings consistent with congenital Zika virus infection, Zika virus NAAT and IgM testing should be performed on maternal serum and NAAT on maternal urine. If amniocentesis is being performed as part of clinical care, Zika virus NAAT testing of amniocentesis specimens should also be performed.

1.4 In 2017, the CDC updated its guidelines on norovirus gastroenteritis outbreak management and disease prevention. Real-time reverse transcription-PCR assays, specifically, TaqMan-based real-time assays, which can contain multiple probes, is considered the effective laboratory diagnostic protocol for testing suspected cases of viral gastroenteritis.

1.5 In 2015, the following recommendations were made for the use of NAATs in diagnosing sexually transmitted diseases

1.5.1 For *Candida* species:

- "PCR testing for yeast is not FDA-cleared; culture for yeast remains the gold standard for diagnosis."

1.5.2 For chlamydia and gonorrhea:

- "NAATs for chlamydia and gonorrhea are recommended because of their high sensitivity and specificity; a specific diagnosis can potentially reduce complications, re-infection, and transmission."
- "Pregnant women found to have chlamydial infection should have a test-of-cure to document chlamydial eradication (preferably by nucleic acid amplification testing [NAAT]) 3–4 weeks after treatment and then retested within 3 months. Screening during the first trimester might prevent the adverse effects of chlamydia during pregnancy, but evidence for such screening is lacking."
- "NAAT performed on rectal specimens is the preferred approach to testing."
- For follow-up, "the use of chlamydial NAATs at <3 weeks after completion of therapy is not recommended because the continued presence of nonviable organisms can lead to false-positive results."

1.5.3 For Chlamydia pneumonia:

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

- NAAT is recommended as an alternative to tissue culture, which “is the definitive standard diagnostic test for chlamydial pneumonia... NAATs are not FDA-cleared for the detection of chlamydia from nasopharyngeal specimens, and clinical laboratories must verify the procedure according to CLIA regulations.”

1.5.4 For *Gardnerella vaginalis*:

- Although PCR has been researched “for the detection of various organisms associated with BV [bacterial vaginosis],” its clinical utility has not yet been established.

1.5.5 For hepatitis C infection:

- NAATs are recommended for screening pregnant women with known risk factors; NAAT “is necessary to confirm the diagnosis of current HCV infection.”
- In addition, “testing for HCV infection should include use of an FDA-cleared test for antibody to HCV...followed by NAAT to detect HCV RNA for those with a positive antibody result.”

1.5.6 For herpes simplex virus:

- “Cell culture and PCR are the preferred HSV tests for persons who seek medical treatment for genital ulcers or other mucocutaneous lesions;” and
- “PCR is the test of choice for diagnosing HSV infections affecting the central nervous system and systemic infections.”

1.5.7 For *Human immunodeficiency virus 1* (HIV-1):

- The use of NAAT is not mentioned; serologic tests are recommended for detecting antibodies against HIV-1 and by virologic tests that detect HIV antigens or RNA.

1.5.8 For human papillomavirus (HPV):

- There are several FDA-cleared HPV tests that detect viral nucleic acid or messenger RNA; however, there are currently no algorithms for HPV 16/18/45 testing in the clinical guidelines;
- The “use of non-oncogenic tests is not recommended;” and
- “HPV assays should be FDA-cleared and used only for the appropriate indications” and should not be performed if the patient is “deciding whether to vaccinate against HPV;” while “conducting STD screening in women or men at risk for STDs;” when “providing

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

care to persons with genital warts or their partners;” when “conducting screening for cervical cancer as a stand-alone test;” when “testing women aged <30 years as part of routine cervical cancer screening;” or when “testing oral or anal specimens.”

1.5.9 For *Trichomonas vaginalis*:

- NAAT is recommended for detecting *T vaginalis* in women due to its high sensitivity and specificity. The APTIMA *T vaginalis* assay (Hologic Gen-Probe, San Diego, CA) is FDA-cleared to detect *T vaginalis* from vaginal, endocervical, or urine specimens for women.
- In 1 study, “[f]or *T vaginalis* diagnosis in men, the sensitivity of self-collected penile-meatal swabs was higher than that of urine.” However, there is currently no FDA-cleared test for men.

1.6 In 2014, the CDC published recommendations regarding the laboratory-based detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infections. It stated:

- NAATs are superior other available diagnostic tests in “overall sensitivity, specificity, and ease of specimen transport;”
- The use of “NAAT to detect chlamydia and gonorrhea except in cases of child sexual assault involving boys and rectal and oropharyngeal infections in prepubescent girls” is supported by evidence; and
- Only NAATs that have been cleared by the FDA for detection of *C trachomatis* and *N gonorrhoea* should be used “as screening or diagnostic tests because they have been evaluated in patients with and without symptoms.”

1.7 In 2009, the CDC published updated guidelines for the use of NAATs in diagnosing *Mycobacterium tuberculosis* bacteria. The CDC recommended that “NAA testing be performed on at least one respiratory specimen from each patient with signs and symptoms of pulmonary TB for whom a diagnosis of TB is being considered but has not yet been established, and for whom the test result would alter case management or TB control activities.” Although it noted that “culture remains the gold standard for laboratory confirmation of TB and is required for isolating bacteria for drug-susceptibility testing and genotyping,” the guideline stated that “NAA testing should become standard practice for patients suspected to have TB, and all clinicians and public health TB programs should have access to NAA testing for TB to shorten the time needed to diagnose TB from 1–2 weeks to 1–2 days.”

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

B. National Institute of Health et al

2.1 The National Institute of Health (NIH), CDC, and HIV Medicine Association of the Infectious Diseases Society of America (IDSA) published guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. In these guidelines, NAATs are discussed in the following situations:

2.1.1 *Bartonella* species

- For patients with suspected bacillary angiomatosis, serologic tests are the standard of care for diagnosing *Bartonella* infection. There are PCR methods that have been developed for identification and speciation of *Bartonella* but they are not widely available.

2.1.2 *Clostridioides (Clostridium) difficile*

- Routine testing with PCR is necessary for patients with diarrhea who have “recently received or are currently receiving antibiotics or cancer chemotherapy, those who have been hospitalized in the past 4 to 6 weeks, those who reside in a long-term care facility, those with CD4 counts <200 cells/mm³, those taking acid-suppressive medications, and those with moderate-to-severe community-acquired diarrhea.”

2.1.3 Cytomegalovirus

- For patients with suspected CMV disease, “viremia can be detected by PCR” and “a positive result is highly suggestive that CMV is the cause of end-organ disease. However, PCR assays are not standardized; therefore, sensitivity, specificity, and interassay comparability are not clearly delineated.”

2.1.4 Hepatitis B

- The CDC, the United States Preventive Services Task Force, and the American Association for the Study of Liver Disease (AASLD) recommend that patients with HIV infection should be tested for hepatitis B; however, NAATs are not recommended for initial testing in patients with HIV.

2.1.5 Hepatitis C

- Patients with HIV are recommended to undergo routine hepatitis C screening, initially “performed using the most sensitive immunoassays licensed for detection of antibody to

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

HCV in blood.” The use of NAATs are not mentioned for initial testing in patients with HIV.

2.1.6 Herpes Simplex Virus

- “HSV DNA PCR and viral culture are preferred methods for diagnosis of mucocutaneous lesions potentially caused by HSV.”

2.1.7 *Mycobacterium tuberculosis* infection and disease

- “Rapid diagnosis is essential in patients with HIV given the risk of rapid clinical progression of TB among patients with advanced immunodeficiency. NAA tests provide rapid diagnosis of TB.”
- “NAA tests have at least two uses among patients with suspected HIV-related TB. First, NAA assays, if positive, are highly predictive of TB disease when performed on AFB smear-positive specimens.... Second, NAA tests are more sensitive than AFB smear, being positive in 50% to 80% of smear-negative, culture-positive specimens and up to 90% when three NAA tests are performed. Therefore, it is recommended that for all patients with suspected pulmonary TB, a NAA test be performed on at least one specimen.”

C. Infectious Disease Society of America et al

Since 2008, the IDSA has partnered with various societies to publish 9 recommendations regarding the use of NAATs to diagnose the viruses and infections discussed in this evidence review.

3.1 In 2018, the IDSA and the American Society for Microbiology published a guide on the diagnosis of infectious diseases. In this guideline, NAATs were recommended diagnostic procedures for enterovirus, hepatitis C, hepatitis B, cytomegalovirus, herpes simplex virus, human herpesvirus 6, HIV, influenza virus, and Zika virus. For bacterial vaginosis, NAATs were not recommended diagnostic procedures. In addition to providing guidance on diagnosing these diseases, the guidelines also provided recommendations on testing for other conditions by testing for common etiologic agents. Table 3 describes the conditions for which IDSA recommends NAATs for diagnosing etiologic agents.

Table 3. IDSA Recommended Conditions for Use of NAATs in Identifying Etiologic Agents of Other Conditions*

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

Etiologic Agents	Recommended Conditions for Use of NAATs in Diagnosis when Specific Etiologic Agents is Suspected
<i>Bartonella</i> spp	Bloodstream infections
<i>Chlamydia pneumoniae</i>	Bronchiolitis, bronchitis, and pertussis; community- acquired pneumonia
<i>Chlamydia trachomatis</i>	Periocular structure infections/ conjunctivitis, orbital and periorbital cellulitis, and acral and eyelid infections; proctitis; epididymitis and orchitis; pathogens associated with cervicitis/ urethritis; pathogens associated with pelvic inflammatory disease and endometritis
<i>Clostridioides (Clostridium) difficile</i>	Gastroenteritis, infectious, and toxin- induced diarrhea
Cytomegalovirus	Pericarditis and myocarditis ^a ; encephalitis; pneumonia in the immunocompromised host; esophagitis; gastroenteritis, infectious, and toxin- induced diarrhea; burn wound infections ^b
Enterovirus	Meningitis; encephalitis; bronchiolitis, bronchitis, and pertussis; community- acquired pneumonia; gastroenteritis, infectious, and toxin- induced diarrhea
Herpes simplex virus	Meningitis; encephalitis; immunocompromised host; esophagitis; proctitis; pathogens associated with cervicitis/ urethritis; burn wound infection ^b ; periocular structure infections/ conjunctivitis, orbital and periorbital cellulitis, and acral and eyelid infections; periocular structure infections/ keratitis; pharyngitis; genital lesions
HIV	Pericarditis and myocarditis; meningitis ^c ; pharyngitis ^c
Human herpesvirus 6	Encephalitis
Influenza virus	Encephalitis; bronchiolitis, bronchitis, and pertussis; community- acquired pneumonia; hospital- acquired pneumonia and

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

	ventilator- associated pneumonia; pulmonary infections in cystic fibrosis
<i>Legionella</i> spp	community- acquired pneumonia; hospital- acquired pneumonia and ventilator- associated pneumonia; infections of the pleural space; surgical site infections
<i>Mycobacteriaspecies-</i> both tuberculosis and NTM	Community- acquired pneumonia; infections of the pleural space; osteomyelitis
<i>Neisseria gonorrhoeae</i>	Pharyngitis; proctitis; native joint infection and bursitis; epididymitis and orchitis; pathogens associated with cervicitis/ urethritis; pathogens associated with pelvic inflammatory disease and endometritis
<i>Staphylococcus aureus</i>	Burn wound infections for MRSA and <i>S aureus</i> only ;trauma-associated cutaneous infections; surgical site infections
<i>Streptococcus</i> , group A	Pharyngitis
<i>Trichomonas vaginalis</i>	Pathogens associated with cervicitis/ urethritis; pathogens associated with pelvic inflammatory disease and endometritis

* The IDSA provided recommendations for many situations in which NAATs are recommended for diagnosing certain etiologic agents commonly seen, with the listed conditions noted under the Recommended Conditions for Use of NAATs in Diagnosis Column. HIV: human immunodeficiency virus; IDSA: Infectious Disease Society of America; M RSA: methicillin-resistant *Staphylococcus aureus*; NAAT: nucleic acid amplification test; NTM: nontuberculous mycobacteria.

^a Recommended as first choice if available.

^b Where applicable and laboratory-validated.

^c The guidelines caution that NAAT is not 100% sensitive in individuals with established HIV infection due to viral suppression; therefore, if NAAT is used, subsequent serologic testing is recommended.

Use of NAATs for diagnosing *Candida* species, *Gardnerella vaginalis*, *Streptococcus* group B, and vancomycin-resistant *Enterococcus* as etiologic agents was not recommended.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

3.2 In 2017, the IDSA published clinical practice guidelines for the management of healthcare-associated ventriculitis and meningitis. When making diagnostic recommendations, the IDSA notes cultures as the standard of care in diagnosing healthcare-associated ventriculitis and meningitis, but that “nucleic acid amplification tests, such as PCR, on CSF may both increase the ability to identify a pathogen and decrease the time to making a specific diagnosis (weak, low).” (Strength of recommendation and quality of evidence established using the GRADE [Grading of Recommendations Assessment, Development and Evaluation] methodology.)

3.3 In 2008, the IDSA published clinical practice guidelines for the management of encephalitis. The following recommendations were made:

- “Biopsy of specific tissues for culture, antigen detection, nucleic acid amplification tests (such as PCR), and histopathologic examination should be performed in an attempt to establish an etiologic diagnosis of encephalitis (A-III).” (Strength of recommendation level “A indicates good evidence to support recommendation for use.” Quality of evidence level III indicates “evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.”)
- “Nucleic acid amplification tests (such as PCR) of body fluids outside of the CNS may be helpful in establishing the etiology in some patients with encephalitis (B-III).” (Strength of recommendation level B indicates “moderate evidence to support recommendation.” Quality of evidence level III indicates “evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.”)
- “Nucleic acid amplification tests (such as PCR) should be performed on CSF specimens to identify certain etiologic agents in patients with encephalitis (A-III). Although a positive test result is helpful in diagnosing infection caused by a specific pathogen, a negative result cannot be used as definitive evidence against the diagnosis.”
- The use of NAATs was recommended for diagnosing CMV, herpes simplex virus 1 and 2, human herpesvirus 6, *Bartonella henselae*, *Mycoplasma pneumoniae*, and *Mycobacterium tuberculosis*.

3.4 In 2018, the IDSA and the Society for Healthcare Epidemiology of America (SHEA) published weak recommendations with low quality evidence for the use of NAATs to diagnose *Clostridioides (Clostridium) difficile*.

- “The best-performing method (ie, in use positive and negative predictive value) for detecting patients at increased risk for clinically significant *C. difficile* [CDI] infection” is

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

use of a “stool toxin test as part of a multistep algorithm...rather than NAAT along for all specimens received in the clinical laboratory when there are no preagreed institutional criteria for patient stool submission.”

- “The most sensitive method of diagnosis of CDI in stool specimens from patients likely to have CDI based on clinical symptoms” is use of “a NAAT alone or a multistep algorithm for testing...rather than a toxin test alone when there are preagreed institutional criteria for patient stool submission.”

3.5 In 2017, the IDSA published clinical practice guidelines for the diagnosis and management of infectious diarrhea. The following recommendations were made:

- In situations where enteric fever or bacteremia is suspected, “culture-independent, including panel-based multiplex molecular diagnostics from stool and blood specimens, and when indicated, culture-dependent diagnostic testing should be performed” (GRADE: strong, moderate).
- In testing for *Clostridioides (Clostridium) difficile* in patients >2 years of age, “a single diarrheal stool specimen is recommended for detection of toxin or toxigenic *C. difficile* strain (eg, nucleic acid amplification testing)” (GRADE: strong, low).
- NAATs are not recommended for diagnosing CMV.
- It was also noted that “clinical consideration should be included in the interpretation of results of multiple-pathogen nucleic acid amplification tests because these assays detect DNA and not necessarily viable organisms” (GRADE: strong, low).

3. 6 In 2016, the IDSA published updated clinical practice guidelines for managing candidiasis. The guideline noted many limitations of PCR testing. No formal recommendation was made, but the guidelines did state that “the role of PCR in testing samples other than blood is not established.”

3. 7 In 2020, the IDSA established a panel composed of 8 members including frontline clinicians, infectious diseases specialists and clinical microbiologists who were members of the IDSA, American Society for Microbiology, Society for Healthcare Epidemiology of America (SHEA), and the Pediatric Infectious Diseases Society (PIDS). Panel members represented the disciplines of adult and pediatric infectious diseases, medical microbiology, as well as nephrology and gastroenterology. The panel created a COVID-19 diagnosis guideline using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for evidence assessment; and, given the need for rapid response to an urgent public health crisis, the methodological approach was

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

modified according to the GIN/McMaster checklist for development of rapid recommendations. The panel published recommendations for COVID-19 diagnosis in an online format, as when substantive new information becomes available the recommendations will require frequent updating. The current recommendations (published December 23, 2020) support *Severe acute respiratory syndrome coronavirus 2* (SARS-CoV-2) nucleic acid testing for the following groups:

- all symptomatic individuals suspected of having COVID-19;
- asymptomatic individuals with known or suspected contact with a COVID-19 case;
- asymptomatic individuals with no known contact with COVID-19 who are being hospitalized in areas with a high prevalence of COVID-19 in the community;
- asymptomatic individuals who are immunocompromised and being admitted to the hospital, regardless of COVID-19 exposure;
- asymptomatic individuals prior to hematopoietic stem cell transplant or solid organ transplantation, regardless of COVID-19 exposure;
- asymptomatic individuals without known exposure to COVID-19 undergoing major time-sensitive surgeries;
- asymptomatic individuals without a known exposure to COVID-19 who are undergoing a time-sensitive aerosol generating procedure (eg, bronchoscopy) when personal protective equipment (PPE) is limited, and testing is available;
- asymptomatic individuals without known exposure when the results will impact isolation/quarantine/ PPE usage decisions, dictate eligibility for surgery, or inform administration of immunosuppressive therapy.

The IDSA panel further recommends the following:

- collecting nasopharyngeal swab, mid-turbinate swab, anterior nasal swab, saliva or a combined anterior nasal/oropharyngeal swab rather than oropharyngeal swabs alone for SARS-CoV-2 RNA testing in symptomatic individuals with upper respiratory tract infection or influenza like illness suspected of having COVID-19 (conditional recommendation, very low certainty of evidence).
- nasal and mid-turbinate swab specimens may be collected for SARS-CoV-2 RNA testing by either patients or healthcare providers, in symptomatic individuals with upper respiratory tract infection or influenza like illness suspected of having COVID-19 (conditional recommendation, low certainty of evidence).
- a strategy of initially obtaining an upper respiratory tract sample (e g, nasopharyngeal swab) rather than a lower respiratory sample for SARS-CoV-2 RNA testing in hospitalized

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

patients with suspected COVID-19 lower respiratory tract infection. If the initial upper respiratory sample result is negative, and the suspicion for disease remains high, the IDSA panel suggests collecting a lower respiratory tract sample (e.g., sputum, bronchoalveolar lavage fluid, tracheal aspirate) rather than collecting another upper respiratory sample (conditional recommendations, very low certainty of evidence)

- performing a single viral RNA test and not repeating testing in symptomatic individuals with a low clinical suspicion of COVID-19 (conditional recommendation, low certainty of evidence).
- repeating viral RNA testing when the initial test is negative (versus performing a single test) in symptomatic individuals with an intermediate or high clinical suspicion of COVID-19 (conditional recommendation, low certainty of evidence).
- using either rapid RT-PCR or standard laboratory-based NAATs over rapid isothermal NAATs in symptomatic individuals suspected of having COVID-19 (conditional recommendation, low certainty of evidence).

D. American Society of Transplantation

4.1 In 2019, the American Society of Transplantation Infectious Diseases Community of Practice published guidelines which addressed vancomycin-resistant enterococci infections in solid organ transplant patients. The guidelines noted the cost-effectiveness and accuracy of “emerging molecular diagnostics for VRE colonization, including multiplexed PCR performed after culture on selective media,” compared with culture alone.

E. American Academy of Pediatrics

5.1 The 2018 edition of the American Academy of Pediatrics (AAP) Red Book describes the diagnostic and treatment options for many infectious diseases in the pediatric population. Their recommendations for appropriate diagnostic tests for the viruses and infections discussed in this policy are detailed in Table 4.

Table 4. Red Book Diagnostic Test Recommendations for the Pediatric Population

Infection	Diagnostic Test Recommendation
-----------	--------------------------------

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

<i>Bartonella henselae</i>	IFA NAAT (PCR)
<i>Candida</i> species	Clinical evaluation microscopy
<i>Chlamydia pneumoniae</i>	Serologic antigen test PCRs- “can provide a specific diagnosis but are not available in most clinical laboratories”
<i>Chlamydia trachomatis</i>	NAATs are recommended for <i>C trachomatis</i> urogenital infections and in postpubescent individuals. They are not recommended for diagnosing <i>C trachomatis</i> conjunctivitis or pneumonia or in the evaluation of prepubescent children for possible sexual assault.
<i>Clostridioides (Clostridium) difficile</i>	Anaerobic cultures of wound exudate and blood should be performed.
Cytomegalovirus	Saliva PCR is the preferred diagnostic tool for screening.
Enterovirus	Reverse-transcriptase PCR and culture from a variety of specimens
<i>Gardnerella vaginalis</i>	Microscopy Numerous NAATs have been recommended when microscopy is unavailable
Hepatitis B	Serologic antigen tests NAATs
Hepatitis C	IgG antibody enzyme immunoassays NAATs
Herpes simplex virus	Cell culture NAATs- diagnostic method of choice for neonates with CNS infections, older children, and adults with HSE
Human herpesvirus 6	Few developed assays are available commercially and do not differentiate between new, past, and reactivated infection. Therefore, these tests “have limited utility in clinical practice.”

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

	Serologic tests; PCR- the assays are not sensitive in younger children.
HIV 1	HIV DNA PCR- “preferred test to diagnose HIV-1 subtype B infection in infants and children younger than 18mo; HIV RNA PCR- “preferred test to identify non-B subtype HIV-1 infections... DNA PCR is generally preferred because of greater clinical experience with that assay.”
Human papillomavirus	“Detection of HPV infection is based on detection of viral nucleic acid or capsid protein.”
Influenza virus	“RT-PCR, viral culture tests, and rapid influenza molecular assays offer potential for high sensitivity as well as specificity and are recommended as the tests of choice.”
<i>Legionella pneumophila</i>	BCYE media Legionella antigen in urine Direct IFA Genus-specific PCR reaction-based assays
Meningitis	Cultures of blood and CSF NAATs- “useful in patients who receive antimicrobial therapy before cultures are obtained.”
<i>Mycobacteriaspecies</i>	<i>M tuberculosis</i> disease: Chest radiography and physical examination While several NAATs are cleared by the FDA, “further research is needed before NAATs can be recommended routinely for the diagnosis of tuberculosis in children,” NTM: “definite diagnosis of NTM disease requires isolation of the organism.”
<i>Mycoplasma pneumoniae</i>	“PCR tests for <i>M pneumoniae</i> are available commercially and increasing replacing other tests, because PCR tests performed on respiratory tract specimens have sensitivity and specificity between

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

	80% and 100%, yield positive results earlier in the course of illness than serologic tests, and are rapid.”
<i>Neisseria gonorrhoeae</i>	“NAATs are far superior in overall performance compared with other <i>N gonorrhoeae</i> culture and nonculture diagnostic methods to test genital and nongenital specimens, but performance varies by NAAT type.”
<i>Staphylococcus aureus</i>	“NAATS are approved for detection and identification of <i>S aureus</i> , including MRSA, in positive blood cultures.”
<i>Streptococcus</i> , group A	“Children with pharyngitis and obvious viral symptoms should not be tested or treated for group A streptococcal infection. Laboratory confirmation is required for cases in children without viral symptoms... culture on sheep blood agar can confirm group A streptococcal infection.”
<i>Streptococcus</i> , group B	“Gram-positive cocci in pairs or short chains by gram stain of body fluids that typically are sterile provide presumptive evidence of infection.”
<i>Trichomonas vaginalis</i>	Microscopy NAATs are “the most sensitive mean of diagnosing <i>T vaginalis</i> infection and is encouraged for detection in females and males.”
Vancomycin-resistant <i>Enterococcus</i>	“Diagnosis is established by culture of usually sterile body fluids with appropriate biochemical testing and serologic analysis for definitive identification.”
Zika virus	NAATs Trioplex real-time PCR assay Serologic testing

BCYE: buffered charcoal yeast extract; CNS: central nervous system; CSF: cerebrospinal fluid; DNA: deoxyribonucleic acid; FDA: Food and Drug Administration; HIV: human immunodeficiency virus; HPV: human papillomavirus; HSE: herpes simplex encephalitis; IFA: indirect fluorescent antibody; MSRA: methicillin-resistant *Staphylococcus aureus*; NAAT:

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

nucleic acid amplification test; NTM: nontuberculous mycobacteria; PCR: polymerase chain reaction; RNA: ribonucleic acid.

5.2 In 2019, the AAP published guidelines on managing infants at risk for group B streptococcus (GBS). It recommends antenatal vaginal-rectal culture performed by using a broth enrichment “followed by GBS identification by using traditional microbiologic methods or by NAAT-based methods.” However, point-of-care NAAT-based screening should not be the primary method of determining maternal colonization status due to reported variable sensitivity as compared with traditional culture, as well as “because most NAAT-based testing cannot be used to determine the antibiotic susceptibility of colonizing GBS isolates among women with a penicillin allergy.”

F. American College of Gastroenterology

6.1 In 2016, the American College of Gastroenterology published clinical guidelines on the diagnosis, treatment, and prevention of acute diarrheal infections in adults. It recommended that, given that “traditional methods of diagnosis (bacterial culture, microscopy with and without special stains and immunofluorescence, and antigen testing) fail to reveal the etiology of the majority of cases of acute diarrheal infection,... the use of FDA-approved culture-independent methods of diagnosis can be recommended at least as an adjunct to traditional methods. (Strong recommendation, low level of evidence).” These are described in the rationale as multiplex molecular testing.

G. American Society for Microbiology

7.1 In 2020, the American Society for Microbiology updated the 2010 guidelines on detecting and identifying GBS that were originally published by the CDC. The guidelines state that “intrapartum NAAT without enrichment has an unacceptably high false negative rate...As such we do not recommend the use of intrapartum NAAT without enrichment to rule out the need for prophylaxis.” All GBS screening specimens should be incubated in selective enrichment broth prior to agar media plating or NAAT. “Nucleic acid amplification-based identification of GBS from enrichment broth is acceptable” for GBS screening, “but not sufficient for all patients” due to high false-negative rates.

U.S. Preventive Services Task Force Recommendations

Not applicable.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

During the Public Health Emergency for the COVID-19 pandemic, a number of Medicare exceptions and waivers have been implemented. For further information on testing, see the Centers for Medicare & Medicaid Services (CMS) website regarding coronavirus disease.

Ongoing and Unpublished Clinical Trials

Some currently ongoing trials that might influence this review are listed in Table 5.

Table 5. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT03452826	Combined Use of a Respiratory Broad Panel MULTIPlex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia: a Multicentre, Parallel-group, Open-label, Randomized Controlled Trial (MULTI-CAP)	450	Aug 2020
NCT03362970	Improvements Through the Use of a Rapid Multiplex PCR Enteric Pathogen Detection Kit in Children With Hematochezia	60	Dec 2021
NCT03840603	PROARRAY: Impact on PCT+ FilmArray RP2 Plus Use in LRTI Suspicion in Emergency Department	444	Dec 2021
NCT04835818	Clinical Impact on Point-of-Care Multiplex Polymerase Chain Reaction (PCR) Testing for Critically Ill Adult Patients With Community-acquired Pneumonia	60	Dec 2021

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

NCT04651712	The Effect of a Point-of-care Sputum Specimen Assay on Antibiotic Treatment of Patients Admitted Acutely With Suspected Pneumonia: A Multicenter Randomized Controlled Trial	200	Dec 2021
NCT04547556	ADEQUATE Advanced Diagnostics for Enhanced QUALITY of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms	1600	Jun 2022
NCT04781530	ADEQUATE Advanced Diagnostics for Enhanced QUALITY of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms - Paediatric	900	Jun 2022
NCT04660084	Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP in Norway: a Pragmatic Randomised Controlled Trial	1060	Dec 2022
<i>Unpublished</i>			
NCT03809117	A Randomized Controlled Trial of Biofire Film Array Panel Compared to Usual Care for Evaluation of Acute Infectious Diarrhea in the Emergency Department	176	Nov 2019 (Unknown)
NCT03895281	Clinical Evaluation of the FilmArray [®] Meningitis/Encephalitis (ME) Panel	150	Apr 2020 (Unknown)

NCT: national clinical trial.

References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, “Identification of Microorganisms Using Nucleic Acid Probes”, 2.04.10, 07:2021.
2. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, “Multitarget Polymerase Chain Reaction Testing for Diagnosis of Bacterial Vaginosis”, 2.04.127, 01:2021.
3. He T, Kaplan S, Kamboj M, et al. Laboratory Diagnosis of Central Nervous System Infection. *Curr Infect Dis Rep*. Nov 2016; 18(11): 35. PMID 27686677

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

15. Evaluation of automatic class III designation (de novo) for xTAG gastrointestinal pathogen panel (GPP) decision summary. Food and Drug Administration. https://www.accessdata.fda.gov/cdrh_docs/reviews/K121454.pdf.
16. Claas EC, Burnham CA, Mazzulli T, et al. Performance of the xTAG(R) gastrointestinal pathogen panel, a multiplex molecular assay for simultaneous detection of bacterial, viral, and parasitic causes of infectious gastroenteritis. *J Microbiol Biotechnol.* 2013; 23(7): 1041-5. PMID 23711521
17. Buchan BW, Olson WJ, Pezewski M, et al. Clinical evaluation of a real-time PCR assay for identification of Salmonella, Shigella, Campylobacter (Campylobacter jejuni and C. coli), and shiga toxin-producing Escherichia coli isolates in stool specimens. *J Clin Microbiol.* Dec 2013; 51(12): 4001-7. PMID 24048539
18. Al-Talib H, Latif B, Mohd-Zain Z. Pentaplex PCR assay for detection of hemorrhagic bacteria from stool samples. *J Clin Microbiol.* Sep 2014; 52(9): 3244-9. PMID 24958797
19. Jiang Y, Fang L, Shi X, et al. Simultaneous detection of five enteric viruses associated with gastroenteritis by use of a PCR assay: a single real-time multiplex reaction and its clinical application. *J Clin Microbiol.* Apr 2014; 52(4): 1266-8. PMID 24478418
20. Freeman K, Mistry H, Tsertsvadze A, et al. Multiplex tests to identify gastrointestinal bacteria, viruses and parasites in people with suspected infectious gastroenteritis: a systematic review and economic analysis. *Health Technol Assess.* Apr 2017; 21(23): 1-188. PMID 28619124
21. Kosai K, Suzuki H, Tamai K, et al. Multicenter evaluation of Verigene Enteric Pathogens Nucleic Acid Test for detection of gastrointestinal pathogens. *Sci Rep.* Feb 04 2021; 11(1): 3033. PMID 33542335
22. Cybulski RJ, Bateman AC, Bourassa L, et al. Clinical Impact of a Multiplex Gastrointestinal Polymerase Chain Reaction Panel in Patients With Acute Gastroenteritis. *Clin Infect Dis.* Nov 13 2018; 67(11): 1688-1696. PMID 29697761
23. Beal SG, Tremblay EE, Toffel S, et al. A Gastrointestinal PCR Panel Improves Clinical Management and Lowers Health Care Costs. *J Clin Microbiol.* Jan 2018; 56(1). PMID 29093106
24. Huang HS, Tsai CL, Chang J, et al. Multiplex PCR system for the rapid diagnosis of respiratory virus infection: systematic review and meta-analysis. *Clin Microbiol Infect.* Oct 2018; 24(10): 1055-1063. PMID 29208560
25. Mansuy JM, Mengelle C, Da Silva I, et al. Performance of a rapid molecular multiplex assay for the detection of influenza and picornaviruses. *Scand J Infect Dis.* Dec 2012; 44(12): 963-8. PMID 22830610

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

26. Dabisch-Ruthe M, Vollmer T, Adams O, et al. Comparison of three multiplex PCR assays for the detection of respiratory viral infections: evaluation of xTAG respiratory virus panel fast assay, RespiFinder 19 assay and RespiFinder SMART 22 assay. *BMC Infect Dis.* Jul 24 2012; 12: 163. PMID 22828244
27. Pierce VM, Hodinka RL. Comparison of the GenMark Diagnostics eSensor respiratory viral panel to real-time PCR for detection of respiratory viruses in children. *J Clin Microbiol.* Nov 2012; 50(11): 3458-65. PMID 22875893
28. Andrews D, Chetty Y, Cooper BS, et al. Multiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: a quasi-randomised study assessing impact on length of stay and antimicrobial use. *BMC Infect Dis.* Oct 10 2017; 17(1): 671. PMID 29017451
29. Brendish NJ, Malachira AK, Armstrong L, et al. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. *Lancet Respir Med.* May 2017; 5(5): 401-411. PMID 28392237
30. Cytomegalovirus (CMV) and Congenital CMV Infection: Laboratory Testing. Centers for Disease Control and Prevention. <https://www.cdc.gov/cmvc/clinical/lab-tests.html>. Page last reviewed May 31, 2019.
31. Center for Disease Control and Prevention. Mycoplasma pneumoniae Infections: Diagnostic Methods. <https://www.cdc.gov/pneumonia/atypical/mycoplasma/hcp/diagnostic-methods.html>.
32. MacCannell T, Umscheil CA, Agarwal RK, et al. Guideline for the Prevention and Control of Norovirus Gastroenteritis Outbreaks in Healthcare Settings. CDC. Updated 2/15/17. <https://www.cdc.gov/infectioncontrol/pdf/guidelines/norovirus-guidelines.pdf>.
33. Hall AJ, Vinje J, Lopman B, et al. Updated Norovirus Outbreak Management and Disease Prevention Guidelines. CDC MMWR. Published 3/4/11. <https://www.cdc.gov/mmwr/pdf/rr/rr6003.pdf>.
34. Workowski KA, Bolan GA, Workowski KA, et al. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep.* Jun 05 2015; 64(RR-03): 1-137. PMID 26042815
35. Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae 2014. CDC MMWR. Published 3/14/14. <https://www.cdc.gov/std/laboratory/2014labrec/2014-lab-rec.pdf>.
36. Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis. CDC MMWR. Published 1/16/09. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?s_cid=mm5801a3_e.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

37. NIH Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Updated May 26, 2020. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf.
38. Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. *Clin Infect Dis*. Aug 31 2018; 67(6): e1-e94. PMID 29955859
39. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. *Clin Infect Dis*. Mar 15 2017; 64(6): e34-e65. PMID 28203777
40. Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis*. Aug 01 2008; 47(3): 303-27. PMID 18582201
41. Lee DH, Vielemeyer O. Analysis of overall level of evidence behind Infectious Diseases Society of America practice guidelines. *Arch Intern Med*. Jan 10 2011; 171(1): 18-22. PMID 21220656
42. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis*. Mar 19 2018; 66(7): e1-e48. PMID 29462280
43. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. *Clin Infect Dis*. Nov 29 2017; 65(12): e45-e80. PMID 29053792
44. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. Feb 15 2016; 62(4): e1-50. PMID 26679628
45. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19. Published May 6, 2020. <https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics/>.
46. Nellore A, Huprikar S. Vancomycin-resistant Enterococcus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant*. Sep 2019; 33(9): e13549. PMID 30913322
47. Kimberlin DW, Brady MT, Jackson, MA, et al. Redbook 2018. *Am Acad Peds*.
48. Puopolo KM, Lynfield R, Cummings JJ, et al. Management of Infants at Risk for Group B Streptococcal Disease. *Pediatrics*. Aug 2019; 144(2). PMID 31285392

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

49. Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults. *Am J Gastroenterol*. May 2016; 111(5): 602-22. PMID 27068718
50. Filkins L, Hauser J, Robinson-Dunn B, Tibbetts R, Boyanton B, Revell P. Guidelines for the Detection and Identification of Group B Streptococcus. American Society for Microbiology. Published 3/10/20. <https://asm.org/ASM/media/Policy-and-Advocacy/images/ASM-GBS-guideline-031020.pdf?ext=.pdf>.
51. Centers for Medicare & Medicaid Services Current Emergencies 2020: Coronavirus Disease 2019. Last reviewed May 26, 2020. <https://www.cms.gov/About-CMS/Agency-Information/Emergency/EPRO/Current-Emergencies/Current-Emergencies-page>.

Policy History

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

- | | |
|------------|---|
| 10/08/2015 | Medical Policy Committee review |
| 10/21/2015 | Medical Policy Implementation Committee approval. New Policy. |
| 02/04/2016 | Medical Policy Committee review |
| 02/17/2016 | Medical Policy Implementation Committee approval. Reorganized policy statements and added new pathogens to coverage statements (enterovirus, <i>Legionella pneumophila</i> , <i>Mycoplasma pneumoniae</i> , <i>hominus and genitalium</i> and <i>Bartonella</i> , <i>Megasphaera</i> , BVAB2 and <i>Atopobium vaginae</i> . and for quantified testing for human herpesvirus 6).. <i>Borrelia testing removed from policy</i> . |
| 01/01/2017 | Coding update: Removing ICD-9 Diagnosis Codes and CPT coding update |
| 02/02/2017 | Medical Policy Committee review |
| 02/15/2017 | Medical Policy Implementation Committee approval. No change to coverage. |
| 02/01/2018 | Medical Policy Committee review |
| 02/21/2018 | Medical Policy Implementation Committee approval. Coverage statement revised to track BCBSA. |
| 02/07/2019 | Medical Policy Committee review |
| 02/20/2019 | Medical Policy Implementation Committee approval. No change to coverage. |
| 04/02/2020 | Medical Policy Committee review |

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

- 04/08/2020 Medical Policy Implementation Committee approval. Evidence review limited to central nervous system, gastrointestinal and respiratory pathogen panels. Detailed guidelines documented to support or not support NAAT testing indications for individual pathogens (bacteria and viruses). Policy statements changed accordingly and edited for clarity.
Added investigational statement, “Based on review of available data, the Company considers multitarget polymerase chain reaction testing for the diagnosis of bacterial vaginosis to be investigational.”
 - 09/03/2020 Medical Policy Committee review
 - 09/09/2020 Medical Policy Implementation Committee approval. SARS-CoV-2 added to the eligible for coverage statement. Policy guidelines updated. Added statement saying Respiratory pathogen panel is eligible for coverage for patients with signs and symptoms of a respiratory infection when the result of testing is actionable and likely to guide treatment.
 - 12/11/2020 Coding update
 - 09/02/2021 Medical Policy Committee review
 - 09/08/2021 Medical Policy Implementation Committee approval. No change to coverage.
- Next Scheduled Review Date: 09/2022

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2020 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	0097U, 0140U, 0141U, 0142U, 0151U, 0152U, 87472, 87482, 87483, 87487, 87492, 87503, 87505, 87506, 87507, 87511, 87512, 87525, 87526, 87527, 87530, 87542, 87552, 87557, 87562, 87582, 87592, 87652, 87797, 87798, 87799 Codes added eff 1/1/2021: 81513, 81514
HCPCS	No codes
ICD-10 Diagnosis	All related diagnoses

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Identification of Microorganisms Using Nucleic Acid Probes

Policy # 00488

Original Effective Date: 10/21/2015

Current Effective Date: 10/11/2021

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.